于津浦

　　研究员，二级PI，博士生导师，主要从事肿瘤微环境中免疫逃逸机制的探讨和肿瘤个体化治疗新靶点的筛选。现任中国医药生物技术协会医药生物技术临床应用专业委员会委员、中华医学会会员。

　　受教育经历

　　2005/09-2008/07天津医科大学肿瘤学专业，博士

　　1997/09-2000/07天津医科大学免疫学专业，硕士

　　1992/09-1997/07天津医科大学临床医学专业，学士；

　　研究工作经历

　　2008/11-至今，天津医科大学附属肿瘤医院，副研究员；

　　2003/11-2008/11，天津医科大学附属肿瘤医院，助理研究员；

　　2000/07-2003/11，天津医科大学附属肿瘤医院，实习研究员；

　　近3年发表学术论文

　　1) Yu JP, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783-97.

　　2) Yu JP, Ren X, Chen Y, Liu P, Wei X, Li H, Ying G, Chen K, Winkler H, Hao X. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients. PLoS One. 2013;8(2):e56069.

　　3) Wang Y, Yang BH, Li H, Cao S, Ren XB, Yu JP*. IDO(+) DCs and signaling pathways. Curr Cancer Drug Targets. 2013 Mar;13(3):278-88.

　　4) Yu JP, Sun J, Wang SE, Li H, Cao S, Cong Y, Liu J, Ren X. Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis. Clin Dev Immunol. 2011;2011:469135.

　　5) Yu JP, Ren X, Li H, Cao S, Han Y, Enoki T, Kato I, Cao C, Hao X. Synergistic effect of CH-296 and interferon gamma on cytokine-induced killer cells expansion for patients with advanced-stage malignant solid tumors. Cancer Biother Radiopharm. 2011 Aug;26(4):485-94.

　　6) Yu J, Ren X, Yan F, Li H, Cao S, Chen Y, Sun H, An X, Zhang N, Hao X. Alloreactive natural killer cells promote haploidentical hematopoietic stem cell transplantation by expansion of recipient-derived CD4(+) CD25(+) regulatory T cells. Transpl Int. 2011;24(2):201-12.

　　7) Sun J, Yu JP, Li H, Yang L, Wei F, Yu W, Liu J, Ren X. Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. J Exp Clin Cancer Res. 2011 Sep 14;30:82. (Co-first author)

　　8) Kong F, Li H, Fan Y, Zhang X, Cao S, Yu JP, Ren X, Hao X. Overweight patients achieve ideal body weight following curative gastrectomy resulting in better long-term prognosis. Obes Surg. 2013 May;23(5):650-6.

　　9) Wang Y, Zhang X, Li H, Yu JP, Ren X. The role of miRNA-29 family in cancer. Eur J Cell Biol. 2013 Mar;92(3):123-8.

　　10) Qin AY, Zhang XW, Liu L, Yu JP, Li H, Wang SZ, Ren XB, Cao S. MiR-205 in cancer: an angel or a devil? Eur J Cell Biol. 2013 Feb;92(2):54-60.

　　11) Zheng YW, Li H, Yu JP, Zhao H, Wang SE, Ren XB. Interferon-λs: special immunomodulatory agents and potential therapeutic targets. J Innate Immun. 2013;5(3):209-18.

　　12) Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77.

　　13) Yang L, Ren B, Li H, Yu JP, Cao S, Hao X, Ren X. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 2013 Jan;62(1):65-73.

　　14) Wang P, Yu JP, Yin Q, Li W, Ren X, Hao X. Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway. Neurochem Res. 2012 Oct;37(10):2076-84.

　　15) Li R, Wang C, Liu L, Du C, Cao S, Yu JP, Wang SE, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 2012 Nov;61(11):2125-33.

　　16) Qi Y, Li RM, Kong FM, Li H, Yu JP, Ren XB. How do tumor stem cells actively escape from host immunosurveillance? Biochem Biophys Res Commun. 2012 Apr 20;420(4):699-703.

　　17) Zhang J, Yu JP, Yang L, Li H, Wei F, Zhao H, Yu W, Ren X. Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously. Cancer Immunol Immunother. 2012 Oct;61(10):1653-61.

　　18) Liu R, Li H, Liu L, Yu JP, Ren X. Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol Ther. 2012 Feb 1;13(3):123-9.

　　19) Zhang J, Li H, Yu JP, Wang SE, Ren XB. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 2012 May 1;130(9):1971-80.

　　20) Cao S, Wang YL, Ren XB, Yu JP, Ren BZ, Zhang XW, Zhang WH, Han Y. Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma. Cancer Biother Radiopharm. 2011 Aug;26(4):503-10.

　　21) Li H, Zhao H, Yu JP, Su Y, Cao S, An X, Ren X. Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother. 2011 Nov;60(11):1587-96.

　　22) Zhang R, Li H, Yu JP, Zhao J, Wang X, Wang G, Yao Z, Wei F, Xue Q, Ren X. Immunoactivative role of indoleamine 2,3‑dioxygenase in gastric cancer cells in vitro. Mol Med Rep. 2011 Jan-Feb;4(1):169-73.

　　获得奖励

　　1)于津浦，任宝柱，曹水，李慧，张维红，韩颖，任秀宝，郝希山。活化异基因造血干细胞治疗晚期实体肿瘤的临床研究，天津市人民政府，天津市科技进步三等奖， 2010年(2010JB-3-079)。

　　2)李慧，任宝柱，苏延军，于津浦，曹水，安秀梅，任秀宝，郝希山。DC诱导的CIK细胞治疗非小细胞肺癌的临床与基础研究，天津市人民政府，天津市科技进步二等奖，2009年(2009JB-2-042)。

　　3)任秀宝，李慧，于津浦，曹水，尤健，潘源，黄宗堂，安秀梅，张乃宁，张新伟，张澎，魏枫。恶性实体肿瘤特异性和非特异性免疫细胞治疗基础与临床研究，天津市人民政府，天津市科技进步二等奖，2007年(2007JB-2-016)。